Buy Rating for Phathom Pharmaceuticals Amid Strong Voquezna Prescription Growth
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals' V Oquezna: A Rising Star in GERD Treatment Market
Express News | Phathom Pharmaceuticals Inc - Prices Underwritten Offering at $11.50 per Share
Express News | Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
Buy Rating Justified by Phathom Pharmaceuticals' V Oquezna Market Expansion and Positive Prescription Trends
Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Raises Price Target to $12
Phathom Pharmaceuticals Analyst Ratings
Phathom Pharmaceuticals' Voquezna: A Buy Rating on Breakthrough GERD Treatment and Market Growth Potential
Phathom Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Phathom Pharmaceuticals Outperforms With Voquezna Driving Revenue Growth: Buy Rating Reaffirmed
Phathom Pharmaceuticals Non-GAAP EPS of -$1.25, Revenue of $7.3M
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
Earnings Flash (PHAT) PHATHOM PHARMACEUTICALS Posts Q2 Loss $-1.25 Per Share, Vs. Street Est of Loss $-1.24 Per Share
As Of June 30, 2024, Phathom Pharmaceuticals' Cash And Cash Equivalents Were $276.2M, The Company Believes It Will Have Sufficient Capital To Fund Operations Through The End Of 2026
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Express News | Phathom Pharmaceuticals Q2 Net Income USD -91.446 Million
Press Release: Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update